<DOC>
	<DOCNO>NCT00854503</DOCNO>
	<brief_summary>Type 2 diabetes ( T2D ) , impair glucose regulation consequent hyperglycemia , promote development coronary heart disease . Secondary dyslipidemia often associate T2D enhances risk cardiovascular complication . HMG-CoA reductase inhibitor ( statin ) selectively administrate treatment dyslipidemia , lead significant reduction cardiovascular risk . More recently , revision guideline establish low therapeutic LDL cholesterol goal diabetic patient , require administration high dose statin . However , unclear whether high dose statin therapy could affect glycemic control diabetic patient . Moreover , data regard effect statins insulin-resistance endothelial function controversial .</brief_summary>
	<brief_title>Metabolic Vascular Effects Statins Untreated Dyslipidemic Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Type 2 diabetes good glycemic control , treat metformin alone . Untreated dyslipidemia . BMI &lt; 30 . History cancer . History cardiovascular disease . Any acute cronic illness require administration steroid drug able interfere glucose metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Statins administration diabetic dyslipidemia</keyword>
</DOC>